Methylin (methylphenidate) Disease Interactions
There are 8 disease interactions with Methylin (methylphenidate):
Cns Stimulants (Includes Methylin) ↔ Agitation
Severe Potential Hazard, High plausibility
Applies to: Anxiety/Stress, Neurosis, Psychosis
The use of central nervous system (CNS) stimulants is contraindicated in patients with marked agitation and/or anxiety, since these symptoms may be aggravated. CNS stimulants may also exacerbate symptoms of behavior disturbance and thought disorder in psychotic patients, particularly children. Therapy with CNS stimulants should be administered cautiously in patients with a history of psychosis or a predisposition to agitated states.
Cns Stimulants (Includes Methylin) ↔ Substance Abuse
Severe Potential Hazard, High plausibility
Applies to: Alcoholism, Drug Abuse/Dependence
Central nervous system (CNS) stimulants, especially amphetamines, have significant potential for habituation and abuse. Tolerance, psychological dependence and severe social dysfunction can develop after prolonged use. Frank psychotic episodes may also occur in association with chronic intoxication. Therapy with CNS stimulants should be administered cautiously, if at all, in patients with a history of alcohol or substance abuse. The use of amphetamines is considered by manufacturers to be contraindicated in such patients.
Methylphenidate (Includes Methylin) ↔ Glaucoma
Severe Potential Hazard, Moderate plausibility
Applies to: Glaucoma/Intraocular Hypertension, Glaucoma (Narrow Angle)
The use of methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) is contraindicated in patients with narrow-angle glaucoma or anatomically narrow angles. These agents exhibit sympathomimetic activity and may induce transient mydriasis. In patients with narrow angles, pupillary dilation can provoke an acute attack of angle-closure glaucoma. If possible, methylphenidate should also be avoided in patients with other forms of glaucoma, since mydriasis may occasionally increase intraocular pressure.
Methylphenidate (Includes Methylin) ↔ Hypertension
Severe Potential Hazard, High plausibility
Applies to: Hypertension
Methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer) exhibit sympathomimetic activity and may elevate blood pressure and pulse rate. Therapy with these agents should be administered cautiously in patients with hypertension. Blood pressure should be monitored periodically during therapy.
Methylphenidate (Includes Methylin) ↔ Seizures Disorders
Severe Potential Hazard, High plausibility
Applies to: Seizures
There is some clinical evidence that methylphenidate may lower the seizure threshold, occasionally even in patients without a history of seizures or prior EEG abnormalities. Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with or predisposed to seizures. The medication should be discontinued if seizures occur during its use.
Cns Stimulants (Includes Methylin) ↔ Tics
Moderate Potential Hazard, High plausibility
Applies to: Tic Disorder
Central nervous system (CNS) stimulants have been reported to exacerbate Tourette's syndrome and other motor and phonic tics. Therapy with CNS stimulants, if necessary, should be administered cautiously in patients with tic disorders or family history of Tourette's syndrome. The manufacturers of the CNS stimulants, methylphenidate (racemic) and dexmethylphenidate (the more pharmacologically active d-enantiomer), consider their use to be contraindicated in such patients.
Methylphenidate (Includes Methylin) ↔ Hematologic Toxicity
Moderate Potential Hazard, Low plausibility
Applies to: Bone Marrow Depression/Low Blood Counts
Hematologic toxicity, including thrombocytopenia, easy bruisability, epistaxis, leukopenia, anemia and eosinophilia, has been reported rarely during use of methylphenidate. However, a causal relationship has not been established. Therapy with methylphenidate (racemic) or dexmethylphenidate (the more pharmacologically active d-enantiomer) should be administered cautiously in patients with preexisting blood dyscrasias or bone marrow suppression. Periodic hematologic monitoring may be appropriate in all patients during prolonged therapy.
Methylphenidate Er (Includes Methylin) ↔ Gi Narrowing
Moderate Potential Hazard, High plausibility
Applies to: Gastrointestinal Obstruction
The extended-release formulation of methylphenidate (Concerta) contains a non-deformable material. There have been rare reports of obstructive symptoms in patients with known strictures following the ingestion of similar sustained-release products. The extended-release formulation of methylphenidate should ordinarily not be administered in patients with preexisting severe gastrointestinal narrowing or obstruction, whether pathologic or iatrogenic (e.g., small bowel inflammatory disease, "short gut" syndrome due to adhesions or decreased transit time, past history of peritonitis, cystic fibrosis, chronic intestinal pseudo-obstruction, or Meckel's diverticulum). The medication should only be used in patients who are able to swallow the tablet whole.
You should also know about...
Methylin (methylphenidate) drug Interactions
There are 242 drug interactions with Methylin (methylphenidate)
Methylin (methylphenidate) alcohol/food Interactions
There is 1 alcohol/food interaction with Methylin (methylphenidate)
See also...
Drug Interaction Classification
The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
| Major | Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. |
| Moderate | Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. |
| Minor | Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date, and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. Multum's drug information does not endorse drugs, diagnose patients, or recommend therapy. Multum's drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug of drug combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2012 Multum Information Services, Inc. The information in contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
